Clinigen moves into unlicensed drugs supply with Idis deal

April 24, 2015 7:54 AM

15 0

LONDON, April 24 (Reuters) - British pharmaceutical company Clinigen Group said it would become a leader in the supply of unlicensed medicines to doctors and hospitals with the acquisition of Idis for 225 million pounds ($340 million).

Idis, owned by private equity group CBPE Capital, provides access to unlicensed drugs in oncology, haematology, immunology and other areas in more than 100 countries, Clinigen said on Friday.

Read more

To category page